Latest Azacitidine Stories
Live Webcasts from New York on August 13th and Boston on August 14th SAN DIEGO, Aug. 6, 2014 /PRNewswire/ -- MEI Pharma, Inc.
SAN DIEGO, June 17, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc.
Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company
Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON,
SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S.
DUBLIN, January 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/g3pk2m/epigenetics_drugs) has announced the addition of the "2013
Data from Three Ongoing Phase II Trials of Pracinostat Anticipated by Year End SAN DIEGO, Jan. 14, 2014 /PRNewswire/ -- MEI Pharma, Inc.
- totally perplexed and mixed up.